Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 12/20 | 0.54 |
| ▸ | RARB | P10826 | 11/20 | 0.54 |
| ▸ | RARG | P13631 | 11/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | RXRB | P28702 | 3/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6548975 | 0.89 | RARA (0.43) | RARARARBRARGPGR | |
| SCHEMBL980736 | 0.73 | DHODH (0.55) | RARARARBRARGRXRARXRB | |
| SCHEMBL2610268 | 0.73 | RXRA (0.69) | RARARARBRARGRXRARXRB | |
| SCHEMBL31331712 | 0.73 | RXRA (0.69) | RARARARBRARGRXRARXRB | |
| SCHEMBL6907265 | 0.71 | RARB (0.64) | RARARARBRARGNR2E1PGR | |
| SCHEMBL8706490 | 0.71 | RARB (0.85) | RARARARBRARGNR2E1RXRA | |
| SCHEMBL8706311 | 0.70 | RARB (1.00) | RARARARBRARGNR2E1RXRA | |
| Benzoic Acid SCHEMBL28361078 | 0.67 | KMO (0.66) | RXRARXRBDHODH | |
| SCHEMBL31266609 | 0.67 | RARB (1.00) | RARARARBRARGMEN1THRB | |
| SCHEMBL3453631 | 0.67 | RARB (1.00) | RARARARBRARGMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122080-A1 | Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| CN-1498105-A | Synergistic combination system for treating cancer comprising a retinoid receptor ligand and a selected cytotoxic agent | ����˹�ж�-����˹˹������˾ | 2004-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122080-A1 | Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.